{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-034708","form_type":"8-K","ticker":null,"cik":"0001403708","company_name":"Evoke Pharma Inc","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.074102+00:00","generated_at":"2026-06-04T09:44:21.237903+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Evoke Pharma appoints co-founder Matthew D'Onofrio as CEO, succeeding Dave Gonyer effective March 31, 2024","bullets":["Dave A. Gonyer resigns as CEO and Board member effective March 31, 2024 for personal reasons; no disagreement with Company.","Matthew J. D'Onofrio appointed CEO and Board member effective March 31, 2024.","D'Onofrio is co-founder, previously President, COO, Secretary and Treasurer since February 2023.","No family relationships or material interests in transactions requiring disclosure."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-034708","json":"https://secwatch.observer/filing/0000950170-24-034708.json","markdown":"https://secwatch.observer/filing/0000950170-24-034708.md","text":"https://secwatch.observer/filing/0000950170-24-034708.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1403708/000095017024034708/0000950170-24-034708-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1403708/000095017024034708/evok-20240320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:44:21.237903+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3b3bb664d5","claim":"Dave A. Gonyer resigned as Chief Executive Officer at Evoke Pharma Inc.","evidence_excerpt":"who is resigning effective as of March 31, 2024, for personal reasons.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1403708/000095017024034708/0000950170-24-034708-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"8907ac6e07","claim":"Matthew J. D'Onofrio was appointed as Chief Executive Officer at Evoke Pharma Inc.","evidence_excerpt":"appointed Matthew J. D’Onofrio as the Company’s Chief Executive Officer, effective as of March 31, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1403708/000095017024034708/0000950170-24-034708-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}